1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Lipoxygenase

Lipoxygenase

LOX

Lipoxygenases (LOXs) are a family of enzymes that are responsible for the metabolism of arachidonic and docosahexaenoic acid and for the formation of several eicosanoids and docosanoids, including leukotrienes, lipoxins and neuroprotectins. Depending on cells' redox state and other milieu conditions, these enzymes are engaged in oxidative stress and cell death mechanisms or in cell protection. Lipoxygenases are lipid peroxidizing enzymes, implicated in the pathogenesis of inflammatory and hyperproliferative diseases, which represent potential targets for pharmacological intervention.

Lipoxygenases are classified on the basis of site of arachidonate oxygenation into 5-, 8-, 9-, 11-, 12- and 15-LOX. The prominent animal LOXs are 5-LOX, 8-LOX, 12-LOX and 15-LOX, while the plant LOXs are mostly 5-LOX and 15-LOX. Among these, 5-LOX is the most predominant isoform associated with the formation of 5-hydroperoxyeicosatetraenoic acid (5-HpETE) and other bioactive lipid mediators.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-100148
    ICI 211965
    Inhibitor
    ICI 211965 (ZM-211965) is a selective and orally potent 5-Lipoxygenase (5-LPO) inhibitor.
    ICI 211965
  • HY-159169
    5-LOX/sEH-IN-1
    Inhibitor
    5-LOX/sEH-IN-1 (Compound 8o) is a dual 5-LOX/sEH-IN-1 inhibitor with cardioprotective effects, exhibiting IC50 values of 3.05 μM and 2.20 nM respectively, and 5-LOX/sEH-IN-1 can also inhibit the activity of COX-2 (IC50=10.50 μM). 5-LOX/sEH-IN-1 has analgesic and anti-inflammatory effects, while reducing ulcer pathogenicity, and can be used to develop anti-inflammatory agents with fewer gastrointestinal and cardiovascular side effects.
    5-LOX/sEH-IN-1
  • HY-B1452S1
    Licofelone-d6
    Licofelone-d6 is the deuterium labeled Licofelone[1]. Licofelone (ML-3000) is a dual COX/5-lipoxygenase (5-LOX) inhibitor (IC50=0.21/0.18 μM, respectively) for the treatment of osteoarthritis. Licofelone exerts anti-inflammatory and anti-proliferative effects. Licofelone induces apoptosis, and decreases the production of proinflammatory leukotrienes and prostaglandins[2][3][4].
    Licofelone-d<sub>6</sub>
  • HY-124674
    CCT365623
    CCT365623 is a potent and orally active LOX inhibitor with an IC50 of 0.9 μM. CCT365623 has potent anti-metastatic efficacy in vivo.
    CCT365623
  • HY-N8480
    Atractylochromene
    Inhibitor
    Atractylochromene is a potent dual inhibitor of 5-LOX/COX-1 with IC50s of 0.6 and 3.3 μM, respectively.
    Atractylochromene
  • HY-121099
    Cgp 8065
    Inhibitor
    L-689065 is a 5-lipoxygenase inhibitor.
    Cgp 8065
  • HY-151173
    XO/COX/LOX-IN-1
    Inhibitor
    XO/COX/LOX-IN-1 (compound 7i) is a potent xanthine oxidase/cyclooxygenases/lipoxygenases (XO/COX/LOX) inhibitor. XO/COX/LOX-IN-1 can be used in studies of inflammation, cancer and metabolic diseases.
    XO/COX/LOX-IN-1
  • HY-N9115
    Plathymenin
    Inhibitor
    Plathymenin is a flavonoid that can be isolated from Nepalese propolis. Plathymenin is a potent inhibitor of 5-LOX.
    Plathymenin
  • HY-123103
    Linetastine
    Inhibitor
    Linetastine is an orally active and potent 5-Lipoxygenase inhibitor. Linetastine shows antihistamine activity. Linetastine inhibits leukotriene production and antagonizes the effect of histamine. Linetastine inhibits the release of leukotrienes B4 and C4 from calcium ionophore-stimulated human leukocytes.
    Linetastine
  • HY-105396
    L 670630
    Inhibitor
    L 670630 is a potent and orally active inhibitor of 5-lipoxygenase, with the IC50 of 23 nM.
    L 670630
  • HY-19443
    UCB-35440
    Inhibitor
    UCB-35440 is an orally active histamine H1 receptor antagonist and 5-lipoxygenase inhibitor. UCB-35440 inhibits LTB4 formation in human whole blood and reduces polymorphonuclear cell infiltration in mouse models. UCB-35440 inhibits histamine-stimulated bronchoconstriction and reduces skin inflammation in guinea pigs. UCB-35440 can be used for research on asthma and skin inflammation.
    UCB-35440
  • HY-120760
    L-691831
    L-691831 is a ligand for 5-lipoxygenase activating protein binding assays that has utility as a tool for studying 5-lipoxygenase activating protein (FLAP) related activities. L-691831 can be used to measure the affinity of FLAP on the leukocyte membrane for leukotriene synthesis inhibitors, with binding being correlated with inhibition of leukotriene synthesis.
    L-691831
  • HY-101579
    LY 178002
    Antagonist
    LY 178002 is a potent inhibitor of 5-lipoxygenase (5-LPO), phospholipase A2, with IC50 of 0.6 μM for 5-lipoxygenase, inhibits cellular production of LTB4 by human polymorphonuclear leukocytes, and shows relatively weak inhibition on cyclooxygenase.
    LY 178002
  • HY-N11845
    Sigmoidin B
    Inhibitor
    Sigmoidin B, a prenylated flavanone, is a selective 5-lipoxygenase inhibitor. Sigmoidin B is a potent scavenger of the DPPH radical. Sigmoidin B has antigenotoxic activity that inhibits genotoxicity induced by Aflatoxin B1 (HY-N6615), with an IC50 of 18.7 μg/mL. Sigmoidin B has anti-inflammatory activity and antioxidant properties.
    Sigmoidin B
  • HY-173115
    15-LOX-IN-2
    Inhibitor
    15-LOX-IN-2 (Compound 2a) is an orally active COX-2/15-LOX inhibitor and a partial agonist of PPARγ. 15-LOX-IN-2 has anti-inflammatory activity and inhibits the levels of 20-HETE, IL-1β and TNF-α in RAW 264.7 cells treated with LPS (HY-D1056). In addition, 15-LOX-IN-2 has significant glucose uptake capacity in the absence of insulin. 15-LOX-IN-2 can be used for the research of metabolic diseases.
    15-LOX-IN-2
  • HY-121586
    Nafazatrom
    Inhibitor
    Nafazatrom (Bay g 6575) is an orally active cardioprotective agent that protects against ischemic damage. Nafazatrom dose-dependently inhibits neutrophil aggregation, superoxide anion generation, arachidonic acid metabolism, and to a lesser extent the release of β-glucosidase, platelet aggregation or arachidonic acid in vitro. Acid metabolism has no significant effect. In a dog ischemia-reperfusion model, Nafazatrom (10 mg/kg; po) reduced infarct size and the occurrence of arrhythmias and rescued ischemic myocardial function without affecting any hemodynamic changes. The basis of Nafazatrom's cardioprotection may be inhibition of neutrophil function and cellular infiltration in vitro.
    Nafazatrom
  • HY-121987
    15(S)-HEDE
    Inhibitor
    15(S)-HEDE (Compound 8) is an analogue of 15-HEDE (HY-121987A) that inhibits 5-lipoxygenase with an IC50 value of 26 μM. 15(S)-HEDE is promising for research of inflammatory disease.
    15(S)-HEDE
  • HY-112532
    REV 5901
    Inhibitor ≥99.0%
    REV 5901 is a competitive and orally active antagonist of leukotriene receptor, with a Ki of 0.7 μM. REV 5901 is also a 5-lipoxygenase inhibitor. REV 5901 can be used for the research of asthma in which leukotriene release be involved.
    REV 5901
  • HY-113776
    15(S)-HETRE
    Inhibitor
    15(S)-HETRE is the hydroxy-trienoic acid resulting from 15-lipoxygenation of dihomo-γ-linolenic acid. It is an inhibitor of 5-LO in human PMNL with an IC50 value of 4.6 μM. In RBL cells, 15(S)-HETrE inhibits 5-LO, but is about 1/20 as potent as 15(S)-HpETE.
    15(S)-HETRE
  • HY-N3451
    Isothymusin
    Inhibitor
    Isothymusin is a potent anti-oxidant agent. Isothymusin shows radical scavenging activities. Isothymusin shows anti-proliferative activities in cancer cell lines. Isothymusin inhibited the enzymes associated with the promotion stage of cancer, including cycloxygenase- 2 and lipoxygenase-5.
    Isothymusin
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.